Updated: Illumina Presses Ahead With Grail Merger Despite Antitrust Regulators' Opposition

The companies will argue the deal is “pro-competitive and life-saving” at a US Federal Trade Commission administrative trial on 24 August, but the FTC maintains the deal will hinder innovation in the multi-cancer diagnostics market. The merger is also facing regulatory scrutiny in Europe.